Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies
Dong M. Shin(Emory University), Zhuo Georgia Chen(Emory University), Rachel Moreno-Williams(Emory University), Gabriel Sica(Emory University), Scott A. Kono(Emory University), Nabil F. Saba(Emory University), A.R.M. Ruhul Amin(Emory University), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), Melinda M. Lewis(Emory University), Fadlo R. Khuri(American University of Beirut Medical Center), Johann C. Brandes(Emory University), Sufi M. Thomas(University of New Mexico), Amy Y. Chen(Vector (United States)), Hongzheng Zhang(Zhujiang Hospital), Jennifer R. Grandis(University of California, San Francisco), Sreenivas Nannapaneni(GlaxoSmithKline (United States)), Jonathan J. Beitler(Emory University), Hyung Ju C. Shin(Emory University), William J. Grist(Emory University), Susan Müller(Emory University)
Cited by 61
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k